Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer

Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer

Introduction. The treatment strategy for castration-resistant prostate cancer (CRPC) has changed with the approval of several new agents. In 2011, abiraterone acetate was approved for the treatment of metastatic CRPC; however abiraterone is known to cause mineralocorticoid excess syndrome characteri...

Full description

Bibliographic Details
Main Authors:	Yutaka Yamamoto, Yasunori Akashi, Takahumi Minami, Masahiro Nozawa, Keisuke Kiba, Motokiyo Yoshikawa, Akihide Hirayama, Hirotsugu Uemura
Format:	Article
Language:	English
Published:	Hindawi Limited 2018-01-01
Series:	Case Reports in Urology
Online Access:	http://dx.doi.org/10.1155/2018/1414395

Similar Items

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
by: Edgar Linden-Castro, et al.
Published: (2014-01-01)

Quadriplegia secondary to abiraterone-induced severe hypokalemia
by: Jignesh B Rajvanshi, et al.
Published: (2019-01-01)

Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer
by: Sara Campora, et al.
Published: (2016-12-01)

Abiraterone acetate: A novel drug for castration-resistant prostate carcinoma
by: R Nandha
Published: (2012-01-01)

The first experience in using abiraterone acetate in patients with castration-refractory prostate cancer
by: L. M. Rapoport, et al.
Published: (2015-11-01)

Clinical experience with abiraterone acetate application in patients with castration-resistant prostate cancer
by: Ya V Gridneva, et al.
Published: (2014-09-01)

A Study on the Clinical Outcome of Abiraterone Acetate in Castration Resistant Prostate Cancer Patients
by: Aloysius James, et al.
Published: (2018-01-01)

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
by: Rosenberg JE, et al.
Published: (2012-01-01)

Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
by: Ayşe Demirci, et al.
Published: (2021-07-01)

Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation
by: Simon Rauch, et al.
Published: (2016-06-01)

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
by: Yoshinori Yanai, et al.
Published: (2019-07-01)

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels
by: Gustavo Werutsky, et al.
Published: (2019-05-01)

A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer
by: Amit Joshi, et al.
Published: (2020-01-01)

Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate.
by: Martin Boegemann, et al.
Published: (2016-01-01)

The efficacy of abiraterone acetate in treating Taiwanese chemo-refractory metastatic castration-resistant prostate cancer patients
by: Tony Wu, et al.
Published: (2016-12-01)

Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients
by: Brendan A. Daisley, et al.
Published: (2020-09-01)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
by: Mostaghel EA
Published: (2014-01-01)

The short-term efficacy and safety of abiraterone acetate with prednisone in metastatic castration-resistant prostate cancer patients in vghtc
by: Chi-Feng Hung, et al.
Published: (2015-06-01)

Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer
by: Katrin Schlack, et al.
Published: (2016-09-01)

SPECTROPHOTOMETRIC AND LUMINESCENCE DETERMINATION OF ABIRATERONE ACETATE
by: I. I. Leonenko, et al.
Published: (2015-02-01)

A COMPARISON OF THE EFFECTIVENESS OF DIFFERENT TREATMENT REGIMENS WITH THE USE OF ABIRATERONE ACETATE AND DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
by: A. V. Kondrashina, et al.
Published: (2018-05-01)

Author Correction: Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients
by: Brendan A. Daisley, et al.
Published: (2020-12-01)

Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors
by: Elena Verzoni, et al.
Published: (2016-09-01)

PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate
by: España S, et al.
Published: (2020-10-01)

Switching from prednisone to dexamethasone in metastatic castration resistant prostate cancer treated with abiraterone acetate in a multicenter study
by: I. Rivero Belenchón, et al.
Published: (2020-07-01)

Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review
by: Wei Zhang, et al.
Published: (2017-01-01)

Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy
by: Benjamin A. Gartrell, et al.
Published: (2015-08-01)

Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial
by: Carsten-Henning Ohlmann, et al.
Published: (2017-10-01)

Metastatic Castration-Resistant Prostate Cancer: Two Case Reports of Dramatic Response with Abiraterone Acetate in Patients Heavily Pretreated with Chemotherapy
by: Laura Dupuy, et al.
Published: (2013-06-01)

Early abiraterone acetate treatment is beneficial in Japanese castration-resistant prostate cancer after failure of primary combined androgen blockade
by: Takashi Nagai, et al.
Published: (2018-03-01)

Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Moritz Binder, et al.
Published: (2016-07-01)

Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
by: ZhenHeng Wei, et al.
Published: (2021-08-01)

A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment
by: Takashi Kawahara, et al.
Published: (2020-09-01)

Abiraterone Acetate Withdrawal Syndrome: Does It Exist
by: Hélène Gauthier, et al.
Published: (2012-07-01)

Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
by: Zobniw CM, et al.
Published: (2014-08-01)

Real-world experience with abiraterone in metastatic castration-resistant prostate cancer
by: Yasar Ahmed, et al.
Published: (2017-01-01)

Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone
by: Zhenyu Yang, et al.
Published: (2021-08-01)

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
by: Pui S. Tan, et al.
Published: (2014-03-01)

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
by: Pui S. Tan, et al.
Published: (2014-01-01)

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter “real life” study
by: Luca Cindolo, et al.
Published: (2017-11-01)